BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
수요일, 9월 30

Lifecore Biomedical Inc

LFCRNASDAQ
Trade with Public
Trade with Public
$6.59
0.071.07%
가까이에: Sep 28, 5:00 PM EST
$6.60
0.081.23%
프리마켓: 7:05 AM EST
인수합병: Lifecore Biomedical (LFCR) announced it will be acquired by Webster Equity Partners on Monday, September 28, 2026 for $663.7M paid in cash
개요뉴스실적 전망이벤트목표가재무심리지분 현황비교옵션주식 보고서

Lifecore Biomedical Analyst Price Targets

Wall Street analyst price targets and consensus rating for Lifecore Biomedical (LFCR).

Price Target Range — 5 Quarters

Analyst Consensus — 3 Analysts

1Buy
2Hold
Consensus RatingBuy# Analysts3Avg. Consensus PT$8Upside to Avg. PT+21.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →
DateFirmAnalystActionRating ChangePrice Target
Sep 29, 2026Barrington ResearchMichael PetuskyDowngradeOutperform→Market Perform—
Sep 28, 2026William BlairMax SmockDowngradeOutperform→Market Perform—
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Barrington Research Downgrades Lifecore Biomedical to Market Perform

Barrington Research analyst Michael Petusky downgrades Lifecore Biomedical (NASDAQ:LFCR) from Outperform to Market Perform.
Benzinga Newsdesk

PRO
William Blair Downgrades Lifecore Biomedical to Market Perform

William Blair analyst Max Smock downgrades Lifecore Biomedical (NASDAQ:LFCR) from Outperform to Market Perform.
Benzinga Newsdesk

PRO
Barrington Research Maintains Outperform on Lifecore Biomedical, Raises Price Target to $6.5

Barrington Research analyst Michael Petusky maintains Lifecore Biomedical (NASDAQ:LFCR) with a Outperform and raises the price target from $6 to $6.5.
Benzinga Newsdesk

PRO
Barrington Research Maintains Outperform on Lifecore Biomedical, Raises Price Target to $6

Barrington Research analyst Michael Petusky maintains Lifecore Biomedical (NASDAQ:LFCR) with a Outperform and raises the price target from $5.5 to $6.
Benzinga Newsdesk

PRO
Barrington Research Upgrades Lifecore Biomedical to Outperform, Announces $5.5 Price Target

Barrington Research analyst Michael Petusky upgrades Lifecore Biomedical (NASDAQ:LFCR) from Market Perform to Outperform and announces $5.5 price target.
Benzinga Newsdesk

Lifecore Stock Sinks As Delayed Launches Push Growth Further Out

Lifecore stock plunges after earnings miss and weak 2026 outlook, with customer losses and delayed growth plans weighing on shares.
Vandana Singh

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

시장 데이터 제공 Benzinga API

BenzingaBenzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved